Base de dados : MEDLINE
Pesquisa : E02.208.200 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 MEDLINE  
              next record last record
para imprimir
Texto completo
[Au] Autor:Shimauchi A; Naganuma M; Sasaoka S; Hatahira H; Motooka Y; Hasegawa S; Fukuda A; Nakao S; Sakai C; Yokoyama S; Ino Y; Nakamura M; Iguchi K
[Ad] Endereço:Laboratory of Community Pharmacy, Gifu Pharmaceutical University.
[Ti] Título:[Survey of Description on Package Inserts of OTC Drugs].
[So] Source:Yakugaku Zasshi;138(2):259-267, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: The "self-medication tax deduction" system began in Japan in January 2017, allowing people to encourage the use of OTC drugs. Package inserts contain important information for consumers regarding their use. In this study, we first checked whether the items, as required in the notifications of the Japanese Ministry of Health, Labour and Welfare, are described in the package inserts of cold remedies and analgesic antipyretics in OTC drugs. The descriptions of almost all packages checked in this study were based on the notifications, but those of a small number of them were not. Next, we examined the description of the items, unrequired in the notification, but worthy for proper use of drugs; e.g., the description of prohibition for use by "patients with severe hypertension" in case of ibuprofen-containing products, and the description was found in only seven of 180 products. Manufactures should make package inserts along with notifications, including the description for proper use of drugs.
[Mh] Termos MeSH primário: Serviços de Informação sobre Medicamentos
Rotulagem de Medicamentos
Medicamentos sem Prescrição
[Mh] Termos MeSH secundário: Analgésicos
Contraindicações de Medicamentos
Rotulagem de Medicamentos/estatística & dados numéricos
Órgãos Governamentais
Seres Humanos
Medicamentos sem Prescrição/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Antipyretics); 0 (Nonprescription Drugs); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00183

  2 / 2 MEDLINE  
              first record previous record
para imprimir
Texto completo
[Au] Autor:Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
[Ad] Endereço:University of Paris Sud, Gustave Roussy cancer campus, drug development department, 94805 Villejuif cedex, France; University of Paris Sud, Gustave Roussy cancer campus, department of medical oncology, 94805 Villejuif cedex, France.
[Ti] Título:[Atezolizumab (Tecentriq ): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma].
[Ti] Título:Atézolizumab (Tecentriq ) : activité, indication et modalités d'utilisation dans les carcinomes urothéliaux localement avancés ou métastatiques..
[So] Source:Bull Cancer;105(2):140-145, 2018 Feb.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Treatments for patients with metastatic or advanced urothelial carcinomas on progression after first line chemotherapy or unfit for cisplatin are currently limited. Atezolizumab (Tecentriq ) is a monoclonal antibody targeting PD-L1. The first of IMVIGOR 210 phase II trial (NCT02951767) investigated atezolizumab as front line treatment among 119 patients with metastatic urothelial cancer unfit for cisplatin. Response rate was 23% and median overall survival 15.9 months. The second cohort (NCT02108652) included 310 patients whose tumors were progressing after first line platinum-based chemotherapy. Response rate was 15% and median overall survival 7.9 months. Among patients with high PD-L1 expression on infiltrating immune cells (ICs), response rate was 26% and median overall survival 11 months. Atezolizumab was well-tolerated in both cohorts with 66% of treatment-related toxicities including 12% (cohort 1) and 7% (cohort 2) of grade 3-4 adverse events. These results led to an approval by the FDA in United States and the EMA in Europe. In France, atezolizumab was available through an early access agreement by the French National Agency for Medicines and Health Products (ANSM) for patients with metastatic or advanced urothelial carcinomas on progression after first line chemotherapy or unfit for cisplatin. So far, its avaibility in France within the EMA approval is pending its pricing.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/uso terapêutico
Antineoplásicos/uso terapêutico
Carcinoma de Células de Transição/tratamento farmacológico
Neoplasias da Bexiga Urinária/tratamento farmacológico
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/administração & dosagem
Anticorpos Monoclonais/farmacocinética
Antineoplásicos/administração & dosagem
Antineoplásicos/efeitos adversos
Antígeno B7-H1/metabolismo
Carcinoma de Células de Transição/metabolismo
Carcinoma de Células de Transição/mortalidade
Carcinoma de Células de Transição/patologia
Cisplatino/efeitos adversos
Ensaios Clínicos Fase I como Assunto
Ensaios Clínicos Fase II como Assunto
Ensaios Clínicos Fase III como Assunto
Contraindicações de Medicamentos
Seres Humanos
Neoplasias da Bexiga Urinária/metabolismo
Neoplasias da Bexiga Urinária/mortalidade
Neoplasias da Bexiga Urinária/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 0 (B7-H1 Antigen); 52CMI0WC3Y (atezolizumab); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180102
[St] Status:MEDLINE

página 1 de 1

Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde